I always appreciate you post Bio, I'm going to stay in the camp of pseudo progression, I heard the same story in regards to pseudo progression from the Ipilimumab team when they were running the phase 3 trial for melanoma. So what's your opinion on what caused the halt? Take a look at these melanoma trials, Yervoy is a multibillion dollar drug and the response rate really isn't that great. Just think of what DCVax can do? "Moreover, in the pivotal phase 3 trial conducted in previously treated patients with advanced melanoma, the best overall response rate was only 11% for ipilimumab. 25 This was consistent with best overall response rates of 4% to 16% in phase 2 studies of ipilimumab monotherapy (Table 6).36–39"
Market Data 
Markets 
AI
